Novo Nordisk's Wegovy Pill Receives First European Approval for Oral Weight Loss Drug
The European Commission has approved Novo Nordisk's Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related comorbidity. This marks the first GLP-1 receptor agonist available in tablet form for weight management across all EU member states. The approval follows a positive opinion from the European Medicines Agency in May 2026 and is supported by the OASIS clinical trial program, which showed approximately 17% weight loss compared to 3% for placebo. This is the fifth regulatory approval for the Wegovy pill after the US, UK, UAE, and Bahrain. Novo Nordisk plans to introduce the treatment in additional countries during the second half of 2026. The European Commission also approved the Wegovy 7.2 mg injection in a single-dose pen for obesity.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection